Early preclinical development of Mycobacterium tuberculosis amino acid biosynthesis pathway inhibitor DRILS-1398 as a potential anti-TB drug

• Published in: iScience Vol. 28; no. 6; p. 112537
• Main Authors: Biswas, Deepesh, Edwin, Rebecca Kristina, Kumar, K. Shiva, Alam, Anwar, Kumar, Dhiraj, Chakraborty, Sandipan, Bulusu, Gopalakrishnan, Ahmad, Farhan Jalees, Shenoy, Gautham G., Singh, Lakshyaveer, Agarwal, Mansi, Siraj, Fouzia, Oruganti, Srinivas, Misra, Parimal, Ehtesham, Nasreen Zafar, Pal, Manojit, Hasnain, Seyed Ehtesham
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 20.06.2025; Elsevier
• Subjects: Biological sciences; Medical Microbiology; Microbiology; Natural sciences; Pharmacology; Medical Microbiology; Biological sciences; Pharmacology; Microbiology; Natural sciences

The search for new anti-tubercular agents is vital for the fight against Mycobacterium tuberculosis, particularly given the rise of drug-resistant strains. DRILS-1398, a pyrazolo[4,3-d]pyrimidine derivative, was discovered as a potent inhibitor of M.tb chorismate mutase (M.tb-CM) with an IC50 = 3.0...